Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure — EVOLUTION  

Heart Failure Clinical Trial

Official title: Observational Study for Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure (EVOLUTION)

Status Completed

Clinical Trial Summary

This observational study is conducted to assess the evolution of multiple markers of congestion over 4 weeks after a worsening heart failure (WHF) event treated in an outpatient unit

Clinical Trial Description

This is a multicenter, non-randomized, observational study designed to assess the evolution of multiple markers (physical, echocardiographic, and biomarkers) of congestion in 40 patients with chronic heart failure (CHF) treated over 4 weeks with 40 to 120 mg daily oral furosemide after an event of WHF treated in an outpatient unit. Patients at selected centers may participate in a telemetry ancillary study, in which real-time, continuous, non-invasive measurements of physiologic parameters of heart failure will be obtained through use of a wearable medical telemetry device.

Approximately 40 patients with CHF with reduced or mildly reduced left ventricular ejection fraction (EF < 50%) who had an admission for WHF in the preceding 1-12 months and who develop symptoms of WHF over the week before presentation to an outpatient clinic will be enrolled. Patients will attend five outpatient visits over the course of 4 weeks.

At each visit, the patient's vital signs will be measured, clinical assessments (NYHA class, jugular vein distension, peripheral edema score, pulmonary rales) will be performed, and blood samples for central assays will be obtained. Detailed echocardiographic examination will be performed prior to enrolment in the first visit and at Visit 5.

Biomarkers related to cardiac and renal function will be measured in blood and urine samples at each visit. ;

Related Conditions & MeSH terms

• Heart Decompensation
• Heart Failure

• NCT number: NCT05747820
• Study type: Observational
• Source: Corteria Pharmaceuticals
• Status: Completed
• Start date: September 28, 2022
• Completion date: April 27, 2023